| Jansen Hospice And Palliative Care 670 White Plains Road, Suite 213, Scarsdale, NY, 10583 | |
| (914) 787-6158 |
News Archive
ViroPharma Incorporated today announced that it has entered into an exclusive option to acquire Meritage Pharma, Inc., a private company based in San Diego, CA focused on developing oral budesonide suspension (OBS) as a treatment for eosinophilic esophagitis (EoE), a chronic inflammatory disorder of the esophagus.
The discovery of what is believed to be the oldest evidence yet found of a human hereditary genetic disorder has been announced by researchers at the Hebrew University of Jerusalem.
Patrick S. Smith, President and Chief Executive Officer of Curaxis Pharmaceutical Corp., commented today on a new report by the Alzheimer's Association, titled "Generation Alzheimer's – the defining disease of the baby boomers", which demonstrates the devastating impact and size of Alzheimer's disease.
The flame-retardant mixture known as "Firemaster 550" is an endocrine disruptor that causes extreme weight gain, early onset of puberty and cardiovascular health effects in lab animals, according to a new study spearheaded by researchers from North Carolina State University and Duke University.
› Verified 8 days ago
| Name | Jansen Hospice And Palliative Care |
|---|---|
| Location | 670 White Plains Road, Suite 213, Scarsdale, New York |
| Hospice ID | 331525 |
| Category | Part of a hospital |
| Ownership Type | Voluntary Non-profit - Private |
| Profit Type | NON-PROFIT |
| SSA county code | 800 |
News Archive
ViroPharma Incorporated today announced that it has entered into an exclusive option to acquire Meritage Pharma, Inc., a private company based in San Diego, CA focused on developing oral budesonide suspension (OBS) as a treatment for eosinophilic esophagitis (EoE), a chronic inflammatory disorder of the esophagus.
The discovery of what is believed to be the oldest evidence yet found of a human hereditary genetic disorder has been announced by researchers at the Hebrew University of Jerusalem.
Patrick S. Smith, President and Chief Executive Officer of Curaxis Pharmaceutical Corp., commented today on a new report by the Alzheimer's Association, titled "Generation Alzheimer's – the defining disease of the baby boomers", which demonstrates the devastating impact and size of Alzheimer's disease.
The flame-retardant mixture known as "Firemaster 550" is an endocrine disruptor that causes extreme weight gain, early onset of puberty and cardiovascular health effects in lab animals, according to a new study spearheaded by researchers from North Carolina State University and Duke University.
› Verified 8 days ago
| NPI Number | 1568557395 |
| Organization Name | Lawrence Community Health Services |
| Address | 670 White Plains Rd Scarsdale, New York, 10583 |
| Phone Number | (914)787-6158 |
News Archive
ViroPharma Incorporated today announced that it has entered into an exclusive option to acquire Meritage Pharma, Inc., a private company based in San Diego, CA focused on developing oral budesonide suspension (OBS) as a treatment for eosinophilic esophagitis (EoE), a chronic inflammatory disorder of the esophagus.
The discovery of what is believed to be the oldest evidence yet found of a human hereditary genetic disorder has been announced by researchers at the Hebrew University of Jerusalem.
Patrick S. Smith, President and Chief Executive Officer of Curaxis Pharmaceutical Corp., commented today on a new report by the Alzheimer's Association, titled "Generation Alzheimer's – the defining disease of the baby boomers", which demonstrates the devastating impact and size of Alzheimer's disease.
The flame-retardant mixture known as "Firemaster 550" is an endocrine disruptor that causes extreme weight gain, early onset of puberty and cardiovascular health effects in lab animals, according to a new study spearheaded by researchers from North Carolina State University and Duke University.
› Verified 8 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 100.0 | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 97.1 | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | 93.1 | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | 88.6 | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | 98.5 | 97.3 |
| Patients who got timely treatment for shortness of breath | 98.3 | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | 72.9 | 93.3 |
News Archive
ViroPharma Incorporated today announced that it has entered into an exclusive option to acquire Meritage Pharma, Inc., a private company based in San Diego, CA focused on developing oral budesonide suspension (OBS) as a treatment for eosinophilic esophagitis (EoE), a chronic inflammatory disorder of the esophagus.
The discovery of what is believed to be the oldest evidence yet found of a human hereditary genetic disorder has been announced by researchers at the Hebrew University of Jerusalem.
Patrick S. Smith, President and Chief Executive Officer of Curaxis Pharmaceutical Corp., commented today on a new report by the Alzheimer's Association, titled "Generation Alzheimer's – the defining disease of the baby boomers", which demonstrates the devastating impact and size of Alzheimer's disease.
The flame-retardant mixture known as "Firemaster 550" is an endocrine disruptor that causes extreme weight gain, early onset of puberty and cardiovascular health effects in lab animals, according to a new study spearheaded by researchers from North Carolina State University and Duke University.
› Verified 8 days ago
| Home Health Aides | 4 |
| Counselors | 1 |
| Medical Social Workers | 2.5 |
| Physicians | 0.5 |
| Registered Nurses | 9 |
| Other Personnel | 4 |
| Total Employees | 21 |
|---|
News Archive
ViroPharma Incorporated today announced that it has entered into an exclusive option to acquire Meritage Pharma, Inc., a private company based in San Diego, CA focused on developing oral budesonide suspension (OBS) as a treatment for eosinophilic esophagitis (EoE), a chronic inflammatory disorder of the esophagus.
The discovery of what is believed to be the oldest evidence yet found of a human hereditary genetic disorder has been announced by researchers at the Hebrew University of Jerusalem.
Patrick S. Smith, President and Chief Executive Officer of Curaxis Pharmaceutical Corp., commented today on a new report by the Alzheimer's Association, titled "Generation Alzheimer's – the defining disease of the baby boomers", which demonstrates the devastating impact and size of Alzheimer's disease.
The flame-retardant mixture known as "Firemaster 550" is an endocrine disruptor that causes extreme weight gain, early onset of puberty and cardiovascular health effects in lab animals, according to a new study spearheaded by researchers from North Carolina State University and Duke University.
› Verified 8 days ago
| Counselors | 0.25 |
| Licensed Practical or Vocational Nurses | 0.25 |
| Medical Social Workers | 0.25 |
| Registered Nurses | 0.25 |
| Others | 6 |
| Total Volunteers | 7 |
|---|
News Archive
ViroPharma Incorporated today announced that it has entered into an exclusive option to acquire Meritage Pharma, Inc., a private company based in San Diego, CA focused on developing oral budesonide suspension (OBS) as a treatment for eosinophilic esophagitis (EoE), a chronic inflammatory disorder of the esophagus.
The discovery of what is believed to be the oldest evidence yet found of a human hereditary genetic disorder has been announced by researchers at the Hebrew University of Jerusalem.
Patrick S. Smith, President and Chief Executive Officer of Curaxis Pharmaceutical Corp., commented today on a new report by the Alzheimer's Association, titled "Generation Alzheimer's – the defining disease of the baby boomers", which demonstrates the devastating impact and size of Alzheimer's disease.
The flame-retardant mixture known as "Firemaster 550" is an endocrine disruptor that causes extreme weight gain, early onset of puberty and cardiovascular health effects in lab animals, according to a new study spearheaded by researchers from North Carolina State University and Duke University.
› Verified 8 days ago
| Jansen Hospice And Palliative Care Location: 670 White Plains Road, Suite 213, Scarsdale, New York, 10583 Phone: (914) 787-6158 |